Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Signed and dated written informed consent by date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation~2. Male and female patients with a diagnosis of Type 2 Diabetes Mellitus treated with a stable dose of basal insulin with or without concomitant metformin and / or sulfonylurea.~3. Glycosylated hemoglobin A1c (Type A, subtype 1c) of \>7.0% and \< or = 10% at Visit 1 (screening)~4. Suitability for trial participation according to investigator's judgment (evaluating all alternative treatment options and in consideration of the patient completing the study)~5. Age \> or =18 years at Visit 1 (screening)~6. BMI \< or = 45 kg/m2 (Body Mass Index) at Visit 1 (screening)~Exclusion criteria:~1. Patients with poorly controlled hyperglycemia~2. Frequent (at the discretion of the investigator) episodes of hypoglycemic events on basal insulin therapy~3. MI, stroke, or TIA within 3 months prior to obtaining informed consent~4. Impaired hepatic or renal function; gastric surgery; cancer within the last 5 years; blood dyscrasias~6. Treatment with other anti-diabetics, anti-obesity medications, steroids or thyroid hormones, participation in another trial with an investigational drug 7. Pre-menopausal women on insufficient birth control 8. Alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose (Type: EXPERIMENTAL): Patients receive BI 10773 low dose daily
- BI 10773 high dose (Type: EXPERIMENTAL): Patients receive BI 10773 high dose daily
- placebo (Type: PLACEBO_COMPARATOR): Patients receive placebo to match BI 10773 daily

Based on this trial design, predict the completion outcome and termination type (if applicable).